Background: Leukotriene (LT) E 4 is the final active metabolite among the cysteinyl leukotrienes (CysLTs). Animal studies have identified a distinct LTE 4 receptor, suggesting that current cysteinyl leukotriene type 1 (CysLT 1 ) receptor antagonists can provide incomplete inhibition of CysLT responses.
20 mg of montelukast twice daily and placebo for 5 to 7 days in a randomized, double-blind, crossover study (NCT01841164). The PD 20 value was determined at the end of each treatment period based on an increasing dose challenge. Measurements included lipid mediators in urine and sputum cells 4 hours after LTE 4 challenge. Results: Montelukast completely blocked LTE 4 -induced bronchoconstriction. Despite tolerating an at least 10 times higher dose of LTE 4 after montelukast, there was no difference in the percentage of eosinophils in sputum. Urinary excretion of all major lipid mediators increased after LTE 4 inhalation. Montelukast blocked release of the mast cell product prostaglandin (PG) D 2 , as well as release of PGF 2a and thromboxane (Tx) A 2 , but not increased excretion of PGE 2 and its metabolites or isoprostanes. Conclusion: LTE 4 The cysteinyl leukotrienes (CysLTs; leukotriene [LT] C 4 , LTD 4 , and LTE 4 ) are biosynthesized in mast cells and other inflammatory cells and contribute to the pathobiology of asthma by producing bronchoconstriction, increased vascular permeability, inflammatory cell infiltration, mucus production, and smooth muscle proliferation. 1 Although LTC 4 and LTD 4 cause bronchoconstriction and many of the proinflammatory effects in human subjects through activation of the cysteinyl leukotriene type 1 (CysLT 1 ) receptor that is blocked by clinically used antagonists, such as montelukast, the mode of action of LTE 4 in asthmatic patients remains unclear. For example, the relative bronchoconstrictive potency of LTE 4 compared with histamine, methacholine, and the other CysLTs has been reported to be greater in asthmatic patients than in healthy subjects, 2,3 although its absolute potency was lower than those of LTC 4 and LTD 4 . 4, 5 Furthermore, studies in genetically modified mice have demonstrated a receptor that is distinctly sensitive to LTE 4 6 and mediates mucin secretion in the trachea 7 and vascular permeability in the skin. 6 Taken together, the possibility of a distinct E-type receptor in human airways has gained recognition as a potential new target for the treatment of asthma. However, there are no studies in human subjects confirming the presence of such a receptor.
Therefore in this randomized, placebo-controlled, crossover study we set out to characterize the effects of inhaled LTE 4 in asthmatic patients with a particular focus on whether the CysLT 1 receptor was involved. Accordingly, the primary aim of the investigation was to establish the effect of the intervention with the prototype CysLT 1 receptor antagonist montelukast on bronchial responsiveness to increasing dose challenges with inhaled LTE 4 . The secondary aim of the study was to determine the influence of montelukast intervention on airway inflammation after LTE 4 inhalation. This was assessed based on sputum cell counts made after provocations once treatment with placebo or active drug had occurred. We hypothesized that if LTE 4 was inducing airway inflammation through a different receptor than CysLT 1 , its effects on sputum cells would be dose dependent for LTE 4 but independent of whether treated with placebo or montelukast.
Finally, as an exploratory end point, we collected urine during provocations for analysis of lipid mediator excretion. This led to the serendipitous discovery of increased urinary excretion of metabolites of prostaglandin (PG) D 2 , as well as several other potent lipid mediators, after inhalation of LTE 4 . The findings add a new dimension, namely that LTE 4 , in addition to having a direct bronchoconstrictive action, also activates mast cells and other cells to produce secondary responses that can amplify or modify its primary effect.
METHODS
Fourteen patients with mild intermittent asthma according to Global Initiative for Asthma guidelines 8 and 2 patients with aspirin-exacerbated respiratory disease (AERD) were recruited from our clinic and through advertisement. Both patients with AERD had a history of unequivocal severe bronchoconstriction after intake of aspirin-like drugs, and one of them had a positive lysine-aspirin inhalation challenge test result. 9 Inclusion and exclusion criteria and medications are reported in the Methods section in this article's Online Repository at www.jacionline.org.
The Ethical Review Board in Stockholm (Dnr 2011/1016-31/1) and the Swedish Medical Products Agency (Dnr 151:2011/49661) approved the study. The participants provided written informed consent. The study is registered at ClinicalTrials.gov (NCT01841164).
Study design
The study was a double-blind, randomized, placebo-controlled study with a crossover design involving two 5-to 7-day treatment periods during which the subjects received 20 mg of montelukast twice daily and matching placebo, respectively (Fig 1) . The dosing and duration of treatment was selected from published data on montelukast in LTD 4 challenges. 10 At screening, patients' baseline characteristics and airway sensitivity to methacholine and inhaled LTE 4 were obtained (Table I) . A washout period of 7 to 14 days preceded the start of the crossover phase during which inhalation challenge with LTE 4 was repeated on the last day of each period. Urine samples were collected before, during, and after the end of the challenge at hourly intervals for up to 4 hours. For analysis of circulating white blood cells, venous blood samples were drawn before LTE 4 inhalation and at 5 minutes after the last dose. Sputum induction was performed 4 hours after the end of the LTE 4 challenge.
Lung function tests, fraction of exhaled nitric oxide measurement, skin prick tests, and sputum induction Lung function, including spirometry and impulse oscillometry (IOS), measurement of fraction of exhaled nitric oxide (FENO), skin prick tests, and sputum induction were performed as outlined in the Methods section in this article's Online Repository.
Drugs and materials
The CysLT 1 
Bronchoprovocation
LTE 4 was administered for inhalation after nebulization by using a dosimetercontrolled jet nebulizer (Spira Elektro 2; Respiratory Care Center, Hameenlinna, Finland), with pulmonary function measured as FEV 1 . IOS measurements were done before and 5 minutes after the end of the challenge. Challenges were performed in the morning and started by inhalation of the diluent. Provided FEV 1 was stable (ie, not deviating >10%), the postdiluent FEV 1 value was used as a baseline value. Half-log dose increments of LTE 4 solution were inhaled every 10 minutes, and FEV 1 was obtained after each dose increment. Provocation was terminated when FEV 1 had decreased by 20% from the baseline value or the maximum dose of LTE 4 was reached. The PD 20 value was derived by means of linear interpolation from the log-cumulated dose-response curve. Bronchial hyperresponsiveness to methacholine was assessed with a similar protocol but with dose increments every third minute in doubling doses (88.6-45,274 nmol). For the 2 patients with AERD, asthma medications were withheld 24 hours before provocation. The protocols for the provocations are in Tables E3  and E4 in this article's Online Repository at www.jacionline.org.
Measurement of urinary metabolites
Urine was stored at 2708C until assay. COX metabolites of arachidonic acid, LTE 4 , and isoprostanes were measured by using in-house ultraperformance liquid chromatography/tandem mass spectrometry method. 11 Mass spectrometry measurements of PGD 2 metabolites were compared with the enzyme immunoassay for 11b-PGF 2a (Cayman Chemical), as described previously. 12 
Urinary samples from the validation cohort
Urinary samples collected during a previous bronchoprovocation study with LTD 4 in healthy subjects and patients with asthma were analyzed. 13 Samples had been biobanked at 2208C for 12 years.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 6.0c software (GraphPad Software, La Jolla, Calif). PD 20 FEV 1 values for LTE 4 and FENO values were transformed logarithmically, data were presented as geometric means and ranges, and repeated-measures ANOVA was performed. Correlations were performed with Pearson correlation on log-transformed data. Because of nonnormal distribution, data from IOS measurements and total sputum cell counts were presented as medians with ranges, and the Wilcoxon matched-pairs signed rank test was used for analysis. Paired t tests were used to determine changes in percentages of blood differential cell counts, as well as changes in levels of urinary metabolites.
RESULTS

Effects of montelukast on baseline lung function and FENO values
There was no difference in prechallenge baseline lung function and FENO values between the 2 treatment periods (see Table E5 in this article's Online Repository at www.jacionline.org).
Effects of montelukast on airway response to inhaled LTE 4 Montelukast protected effectively against LTE 4 -induced bronchoconstriction: mean maximal FEV 1 decrease was 0.45% (95% CI, 23% to 2.1%) with montelukast compared with 26.3% (95% CI, 223% to 229.6%) after placebo (P < .001) and 28.7% (95% CI, 225.3% to 232%) at screening (Fig 2,  A) . After treatment with montelukast, all subjects tolerated the highest cumulated dose of inhaled LTE 4 (geometric mean, 380,277 pmol), which was, on average, 10-fold higher compared with placebo (geometric mean, 37,006 pmol; P < .001; Fig 2, B) . There was no significant difference in LTE 4 (Table I) . Furthermore, LTE 4 was a relatively more potent bronchoconstrictor in the subjects with the lowest airway hyperresponsiveness to methacholine (Fig 2, C) .
IOS measurements were performed in 11 subjects, including both patients with AERD, to extend the information about the influence of LTE 4 on the airway tree. There was a mean 58.9% change (95% CI, 41.1% to 76.8%) in total airway resistance at 5 Hz after inhalation of LTE 4 with placebo compared with a mean 7.1% change (95% CI, 23.2% to 17.2%) with montelukast (P < .001). With respect to the sensitive markers of small-airway obstruction, 14 frequency-dependent resistance and reactance area, there were 7-and 10-fold increases, respectively, after inhalation of LTE 4 in the presence of placebo. This conspicuous small-airway constriction caused by LTE 4 was abolished by montelukast (Fig 3, A and B) . Changes in all measured IOS parameters during the 2 treatment periods are presented in Table E6 in this article's Online Repository at www.jacionline.org.
Effects of montelukast on white blood cell counts
Five minutes after inhalation of the last dose of LTE 4 , there was an increase in numbers of circulating white blood cells, which was driven by increased numbers of total lymphocytes and associated with a distinct decrease in numbers of eosinophils, whereas neutrophil and monocyte numbers remained the same (see Fig E1 in this article's Online Repository at www.jacionline.org). However, there was no significant difference between placebo and montelukast with respect to these changes in white blood cell counts (see Fig E1) .
Effects of montelukast on sputum cells
Paired data on viable sputum cells were obtained in 9 subjects (including 1 patient with AERD) 4 hours after LTE 4 challenge on the last day of each treatment period. There was no significant difference between placebo and montelukast 6 /g sputum] for placebo and montelukast, respectively; P 5 .039; Fig 3, D) . Other differential cell counts were also similar between the 2 treatment periods (see Fig E2 in Mediator excretion in urine (all data are presented as nanograms per nanomole of creatinine) LTE 4 . As expected, urinary excretion of LTE 4 increased compared with baseline values after inhalation of LTE 4 during both treatment periods (981 6 240 after placebo vs 15 6 10 at baseline, P 5 .0015; 3201 6 645 after montelukast vs 11 6 5 at baseline, P 5 .0002). Peak excretion during montelukast treatment was significantly greater (P 5 .002; Fig 4, A) . There was a consistent 2% recovery of inhaled LTE 4 (1.7% on placebo and 2.4% on montelukast) across the range of inhaled concentrations (Fig 4, B) . PGD 2 metabolites. Levels of the most abundant metabolite, tetranor-PGDM, increased after LTE 4 inhalation on placebo 3, C) and total sputum cell (Fig 3, D) counts from 9 subjects with paired data. The open circle represents values in patient number 2 with AERD. Horizontal bars indicate median (Fig 3, C) and mean (Fig 3, D) values. *P 5 .039. (3743 6 1335 vs 272 6 77 at baseline, P 5 .0189). This increase was completely blocked during montelukast treatment (509 6 101 vs 418 6 135 at baseline, not significant; Fig 5, A) . The early metabolite of the mast cell mediator PGD 2 , 2,3-dinor11b-PGF 2a , showed an identical pattern (Fig 5, B) , although the numeric mean increase during placebo did not reach statistical significance (P 5 .072). We replicated the data for urinary excretion of PGD 2 metabolites observed in the ultraperformance liquid chromatography/tandem mass spectrometry analysis by using a commercially available EIA for the very early PGD 2 metabolite 11b-PGF 2a (Fig 5, C) . However, this metabolite was not detected by using mass spectrometry, extending earlier data indicating that the 10% cross-reactivity of the antibody against 11b-PGF 2a with 2,3-dinor-11b-PGF 2a explains the results of using that particular EIA on urine. 12, 15 We confirmed good agreement between the 2 measurements by using BlandAltman analysis (see Fig E3 in this article' s Online Repository at www.jacionline.org).
Base
Thromboxane B 2 and its metabolites. Levels of the most abundant metabolite, 2,3DN-TXB 2 , increased after LTE 4 inhalation challenge during both treatments (1853 6 460 for placebo vs 201 6 74 at baseline, P 5 .0019; 561 6 116 for montelukast vs 159 6 41 at baseline, P 5 .0021). Peak excretion was significantly greater with placebo (P 5.0092; Fig 6, A) . PGF 2a . PGF 2a levels increased significantly after challenge during placebo treatment (711 6 158 vs 209 6 34 at baseline, P 5 .0029) but did not reach a significant increase during montelukast treatment (411 6 67 vs 251 6 74 at baseline, P 5 .06). Peak excretion was greater during placebo treatment compared with that during the montelukast period (P 5 .0350; Fig 6, B) .
Prostacyclin metabolite 2,3-dinor-6-keto-PGF 1a . This metabolite did not increase significantly after LTE 4 inhalation with either treatment. However, there was a trend (P 5 .055) toward an increased level during placebo treatment (Fig 6, C) . PGE 2 and its metabolites. Urinary excretion of primary PGE 2 increased to the same extent after challenge during both treatment periods (143 6 31 for placebo vs 57 6 21 at baseline, P 5 .0219; 147 6 34 for montelukast vs 69 6 39 at baseline, P 5 .0188; Fig 6, D) . The same was true for the later and more abundant metabolite tetranor-PGEM (1555 6 365 for placebo vs 363 6 111 at baseline, P 5 .0056; 1823 6 407 for montelukast vs 388 6 90 at baseline, P 5 .0037; Fig 6, E) .
Isoprostanes. Levels of the most abundant metabolite, 8,12-iPF 2a -VI, increased after LTE 4 inhalation challenge during both treatments (2139 6 347 for placebo vs 858 6 166 at baseline, P 5 .0035; 1756 6 273 for montelukast vs 1081 6 220 at baseline, P 5 .0274; Fig 6, F) . Results of 8iso-PGF 2a and Analysis of urine collected in a previous LTD 4 bronchoprovocation study 13 found increased urinary excretion of the following compounds after LTD 4 for before versus after differences during each period and lower bars displaying significant differences between periods. *P < .05 and **P < .01.
DISCUSSION
In this controlled study we demonstrate that treatment for 5 to 7 days with the selective CysLT 1 receptor antagonist montelukast effectively inhibited a broad range of responses induced by LTE 4 inhalation. This is the first study in which montelukast, the clinically most widely used CysLT 1 antagonist, has been assessed for its efficacy against airway obstruction induced by LTE 4 . In addition, we discovered that inhaled LTE 4 led to increased urinary levels of several major metabolites of eicosanoid-derived lipid mediators; in particular, increased excretion of metabolites of PGD 2 suggests that the CysLT 1 receptor in vivo can activate mast cells. Furthermore, LTE 4 -induced release of PGD 2 metabolites was blocked by montelukast and replicated by inhalation of LTD 4 , which together lend strong support to the interpretation that this presumed mast cell activation was mediated by the CysLT 1 receptor. In fact, this new finding heralds a new awareness that CysLTs should be reclassified as both directly and indirectly acting bronchoconstrictors.
As expected, this study confirmed that LTE 4 is a more potent bronchoconstrictor than methacholine. Although the bronchoconstrictive properties of LTD 4 have been studied extensively, there are only a handful studies of how the terminal CysLT LTE 4 affects human airways in vivo. Compared with methacholine, LTE 4 was about 70 times more potent on a molar basis. Using an identical challenge protocol, we found that inhaled LTD 4 is approximately 1000 times more potent than methacholine. 13 This confirms the potency differences determined in the few studies in which inhaled LTE 4 has been compared with methacholine or histamine on the one hand and LTC 4 or LTD 4 on the other hand. 3 We also found that the asthmatic patients with the highest hyperresponsiveness for methacholine had the lowest relative airway responsiveness to LTE 4 , which is in perfect agreement with relations established between methacholine and inhaled LTC 4 or LTD 4 levels in previous studies. 13, 17 Furthermore, pretreatment with montelukast abolished bronchoconstriction after inhalation of LTE 4 in all study subjects (14 patients with mild asthma and 2 patients with AERD). During treatment with montelukast, on average, asthmatic patients tolerated a 10-fold higher dose of inhaled LTE 4 compared with placebo without any decrease in lung function. In contrast, during the placebo-treated period, the subjects showed an excellent repeatability of LTE 4 PD 20 measurements determined during screening. Our findings are in agreement with those of previous studies using 2 other LT receptor antagonists against inhaled LTE 4 . 5, 18 The results support that the in vivo effect of LTE 4 on airway smooth muscle in human subjects is mediated exclusively by the CysLT 1 receptor. This agrees with in vitro data in isolated human bronchi and other models in which LTE 4 acts through the CysLT 1 receptor. 1, [19] [20] [21] Because FEV 1 reflects mainly changes to the larger airways, for the first time, this study applied IOS measurements in subjects challenged with LTE 4 . This approach revealed pronounced peripheral airway obstruction after LTE 4 inhalation in the presence of placebo similar to that seen in patients with severe asthma and small-airways disease. 22 In contrast, during treatment with montelukast, there were no signs of small-airways impairment and essentially no significant changes in IOS parameters after LTE 4 inhalation. Interestingly, previous treatment studies with montelukast have indicated that small-airway function in asthmatic patients was improved by montelukast, 23, 24 implicating that endogenous CysLTs contribute to small-airway disease. The small-airway obstruction induced by LTE 4 might be due to both smooth muscle constriction and mucosal edema because CysLTs are potent inducers of plasma exudation, 25 which is also shown in the airways. 26, 27 We deliberately used a higher dose of montelukast (40 mg) than the ordinary clinical 10 mg once-daily dosing. This was because we wished to ensure effective CysLT 1 antagonism to avoid ambiguous data caused by incomplete receptor inhibition by this competitive antagonist. In fact, the only published dose-ranging study of montelukast in the LTD 4 provocation setting has shown progressively increasing shifts in the dose-response relation for LTD 4 up to 250 mg of montelukast. It should be appreciated that montelukast is a very selective CysLT 1 antagonist and that the initial clinical treatment studies used much higher doses (100-200 mg). 28, 29 Interestingly, lung function improvement in these high-dose studies was greater than in subsequent studies using 10 mg, 30 although performed on comparable patient populations. Perhaps it is time to revisit the dosing of montelukast?
Furthermore, despite exposure to one order of magnitude higher dose of LTE 4 in the presence of montelukast, the sputum eosinophil count was the same as during the placebo period. If another receptor had been sensitive to LTE 4 , the substantially higher agonist concentration would have been expected to result in an amplified response. Therefore the finding argues against additional receptors being involved in the proinflammatory effects of LTE 4 on airway cells. Inhaled LTD 4 and LTE 4 levels have been reported to differ with respect to the ability to cause airway eosinophilia. 31 Our study suggests that the outstanding explanation for this observation is unlikely to be related to a different receptor for LTE 4 .
Original work on LT mechanisms in animal airways showed that CysLTs can cause profound release of PGs and other COX products that contribute to the overall biological responses 32, 33 ; however, this mechanism has never been confirmed in human subjects in vivo. For the first time, our study demonstrated that inhaled LTE 4 induces increased urinary excretion of metabolites indicative of pulmonary release of PGE 2 , PGD 2 , PGF 2a , and TXA 2 , as well as several isoprostanes being markers of oxidative stress. 34 Increased excretion of PGD 2 is considered a sign of mast cell activation because this cell is the major source of PGD 2 in human subjects. 12, 35 This increased excretion was abolished by montelukast treatment, confirming it to be CysLT 1 dependent. There are previous experimental data supporting that CysLTs can activate mast cells and cause secondary release of prostanoids. 36, 37 Moreover, we were able to replicate the effect of LTE 4 on PGD 2 release by measurements in urine that had been biobanked after a previous LTD 4 inhalation study. 13 That study also supported dosedependent mast cell activation because it included healthy subjects who tolerated a higher dose of LTD 4 and displayed a more pronounced mediator excretion in urine. Because mast cells also produce CysLTs, the study results raise the hypothesis that CysLT 1 -dependent mast cell activation might represent a positive feedback loop sustaining the response to the initial stimulus. Another implication of this new finding is that eosinophils, which are proficient producers of CysLTs, could prime mast cells by this particular mechanism. The allegation of a prostanoid component in LTinduced airway hyperresponsiveness was previously indicated by the finding of Christie et al 38 that indomethacin blocked the increase in histamine responsiveness that followed LTE 4 inhalation. TXA 2 release and, to some extent, also PGF 2a showed similar sensitivity to inhibition by montelukast. This could be also be due to CysLT 1 -mediated release from mast cells, but secondary release from other sources is also possible. It remains poorly characterized which lipid mediators are formed in human mast cells in vivo. In contrast, increased urinary excretion of PGE 2 and its major metabolite, tetranor-PGEM, were not blocked by montelukast. It is possible that another receptor might be involved in that release, perhaps from the airway epithelium, which is a major source of PGE 2 . 39, 40 However, because the patients received a 10-fold greater dose of LTE 4 in the presence of montelukast without an increase in urinary excretion of PGE 2 , it is also possible that the effect partly involved the CysLT 1 receptor. Irrespective of the receptor involved, it is of considerable interest that inhalation of LTE 4 triggered secondary release of PGE 2 , which has many anti-inflammatory effects on key targets in asthmatic patients, such as mast cells 41, 42 and type 2 innate lymphoid cells. 43, 44 Therefore the finding of increased PGE 2 excretion might be a protective negative feedback response intended to aid resolution. LTE 4 inhalation was also followed by an immediate increase in numbers of circulating lymphocytes and a decrease in eosinophil counts, both effects that were unaffected by montelukast, suggesting that they might be mediated by another receptor. Future studies are required to characterize this new observation in greater detail.
Two patients with AERD were included in the study. Their responses to LTE 4 in no respect differed from the rest of the asthmatic patients, which fits with the remarkably good therapeutic response observed when montelukast was added to conventional therapy with inhaled steroids in this particular asthma phenotype. 45 In conclusion, montelukast inhibited both the bronchoconstriction and mast cell activation that was induced by inhalation of LTE 4 . However, PGE 2 release was not blocked by montelukast, suggesting involvement of another LT receptor for this particular effect, at least in part. Nevertheless, the study unequivocally demonstrates that airway obstruction in response to inhalation of LTE 4 in asthmatic patients is mediated solely by the CysLT 1 receptor.
Clinical implications: Clinically available LT antagonists protect against the airway obstruction and proinflammatory effects of the terminal CysLT LTE 4 .
